NS
Highly rated in
9
conditions

Dr. Nirmish R. Shah

Private Diagnostic Clinic
Durham, NC
Highly rated in
9
conditions
Specialties:Hematology Oncology | Pediatrics
Experience:23 Years
Clinical Trials:Currently Recruiting for 4 Trials
Accepts:New PatientsMedicare
Highly rated in
9
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Nirmish R. Shah's experience treating your condition:
About Dr. Nirmish R. Shah

Nirmish Shah is a Hematologist Oncology specialist and a Pediatrics expert in Durham, North Carolina. Shah has been practicing medicine for over 23 years and is highly rated in 9 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant. He is licensed to treat patients in North Carolina. Shah is currently accepting new patients.

His clinical research consists of co-authoring 94 peer reviewed articles and participating in 16 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Nirmish R. Shah it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Nirmish R. Shah accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Bright Health
  •  Cigna
  •  UnitedHealthcare
  •  Aetna
Call to see if your plan is accepted.
Locations
40 Duke Medicine Cir, Durham, NC 27710
Background & Education
Graduate Institution
Other, 2000
Specialties
Hematology Oncology
Pediatrics
Licenses
Internal Medicine in NC
Hospital Affiliations
Duke University Hospital
Languages Spoken
English
Arabic
Spanish
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Enrollment Status: Recruiting
Publish Date: November 07, 2022
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Enrollment Status: Recruiting
Publish Date: November 07, 2022
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta® (Voxelotor)
Enrollment Status: Recruiting
Publish Date: March 25, 2022
Intervention Type: Drug
Patient-Empowered Mobile Technology in Hospitalized Patients: Technology Resources to Understand Pain Assessment in Patients With Pain (TRU-PAIN)
Enrollment Status: Recruiting
Publish Date: January 25, 2022
Intervention Type: Other
Study Phase: Not Applicable
A Phase 1/2, Open-Label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AB1 in Adult Patients With Sickle Cell Disease (SCD)
Enrollment Status: Not yet recruiting
Publish Date: October 10, 2022
Intervention Type: Drug
Study Drug: AB1
Study Phase: Phase 1/Phase 2
Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization- mESH Study
Enrollment Status: Completed
Publish Date: September 27, 2022
Intervention Type: Behavioral
Study Phase: Not Applicable
A Retrospective Data Collection and Analysis Study of Patients With Sickle Cell Disease (SCD) Who Have Been Treated With Oxbryta® (Voxelotor)
Enrollment Status: Completed
Publish Date: September 07, 2022
Intervention Type: Drug
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
Enrollment Status: Active, not recruiting
Publish Date: April 26, 2022
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
Enrollment Status: Active, not recruiting
Publish Date: April 22, 2022
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 4
Early Low-dose Ketamine Infusion Versus Usual Care for Sickle Cell Pain Crisis: a Randomized, Prospective Study.
Enrollment Status: Withdrawn
Publish Date: January 14, 2022
Intervention Type: Drug, Other
Study Phase: Phase 4
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Biological
Study Phase: Phase 2
Role of Virtual Reality (VR) in Decreasing Pain and Anxiety in Patients With Sickle Cell Disease (SCD)
Enrollment Status: Terminated
Publish Date: March 01, 2021
Intervention Type: Device
Study Phase: Not Applicable
Impact of Daily Prophylaxis Dose Anticoagulation With a Factor Xa Inhibitor (Apixaban) in Patients With Sickle Cell Disease
Enrollment Status: Terminated
Publish Date: March 11, 2020
Intervention Type: Drug
Study Phase: Phase 3
Use of a Mobile-based Pain Assessment Application for SCD Patients
Enrollment Status: Completed
Publish Date: July 16, 2019
Use of Mobile Technology for Intensive Training in Medication Management
Enrollment Status: Completed
Publish Date: May 25, 2017
Intervention Type: Behavioral
Study Phase: Not Applicable
Randomized Double Blind Placebo Controlled Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose LMWH Versus Placebo
Enrollment Status: Completed
Publish Date: February 16, 2015
Intervention Type: Drug
Study Phase: Phase 2
View 12 Less Clinical Trials -
93 Total Publications
Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study.
Journal: JMIR formative research
Published: July 26, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
HF
Dr. Henry S. Friedman
Pediatrics | Hematology Oncology | Neurosurgery
Highly rated in
16
conditions
Pediatrics
Hematology Oncology
Neurosurgery

Duke Health

The Preston Robert Tisch Brain Tumor Center

20 Duke Medicine Cir, 
Durham, NC 
 0.1 mi

Henry Friedman is a Pediatrics specialist and a Hematologist Oncology expert in Durham, North Carolina. Friedman has been practicing medicine for over 46 years and is highly rated in 16 conditions, according to our data. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor. He is licensed to treat patients in North Carolina. Friedman is currently accepting new patients.

DG
Dr. Daniel J. George
Hematology Oncology | Urology
Highly rated in
16
conditions
Hematology Oncology
Urology

Duke Health

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 0.1 mi

Daniel George is a Hematologist Oncology specialist and an Urologist in Durham, North Carolina. George has been practicing medicine for over 31 years and is highly rated in 16 conditions, according to our data. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Orchiectomy, and Prostatectomy. He is licensed to treat patients in North Carolina. George is currently accepting new patients.

DB
Danielle M. Brander
Dr. Danielle M. Brander
Hematology Oncology
Highly rated in
15
conditions
Hematology Oncology

Duke Health

Duke Cancer Center

20 Duke Medicine Cir, 
Durham, NC 
 0.1 mi

Danielle Brander is a Hematologist Oncology expert in Durham, North Carolina. Brander has been practicing medicine for over 16 years and is highly rated in 15 conditions, according to our data. Her top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in North Carolina. Brander is currently accepting new patients.